GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the ...

GSK plc (LSE/NYSE: GSK) has today released global survey data showing that over half (52%) of people aged 50-60 feel younger ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday authorized GSK plc’s (NYSE:GSK) Blenrep.

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the ...